---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-021229"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:08:19.939983+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Trevi Therapeutics reports Q1 net loss of $6.4M; plans three chronic cough trials in H2 2023

## Summary
- Net loss of $6.4M in Q1 2023 vs. $7.3M in Q1 2022; cash and equivalents $111.3M.
- Plans to initiate Phase 2b trial for chronic cough in IPF, Phase 1b respiratory physiology trial, and Phase 2a refractory chronic cough trial in H2 2023.
- Received Notice of Allowance for U.S. patent covering oral nalbuphine ER for chronic cough in IPF, expected expiration 2039.
- Completed open-label extension of Phase 2b/3 PRISM trial for prurigo nodularis; will request End of Phase 2 meeting with FDA.
- Completed part 1 of human abuse potential study; selected butorphanol dose for part 2.

## SEC filing metadata
- accession: 0000950170-23-021229
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000095017023021229/0000950170-23-021229-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000095017023021229/trvi-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-021229
- JSON: https://secwatch.observer/filing/0000950170-23-021229.json
- Plain text: https://secwatch.observer/filing/0000950170-23-021229.txt

## Key facts
- Earnings Releases
  Trevi Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income a net loss of $6.4 million.
  - Period: the quarter ended March 31, 2023
  - Net income: a net loss of $6.4 million
  - Result: reported results
  source text: For the first quarter of 2023, the Company reported a net loss of $6.4 million, compared to a net loss of $7.3 million in the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563880/000095017023021229/0000950170-23-021229-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.